Lv Xiayi, Wu Zhigang, Cao Jinlin, Hu Yeji, Liu Kai, Dai Xiaona, Yuan Xiaoshuai, Wang Yiqing, Zhao Kui, Lv Wang, Hu Jian
Department of Thoracic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Department of Thoracic Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Transl Lung Cancer Res. 2021 Jan;10(1):430-438. doi: 10.21037/tlcr-20-1026.
Accurately predicting the risk level for a lymph node metastasis is critical in the treatment of non-small cell lung cancer (NSCLC). This study aimed to construct a novel nomogram to identify patients with a risk of lymph node metastasis in T1-2 NSCLC based on positron emission tomography/computed tomography (PET/CT) and clinical characteristics.
From January 2011 to November 2017, the records of 318 consecutive patients who had undergone PET/CT examination within 30 days before surgical resection for clinical T1-2 NSCLC were retrospectively reviewed. A nomogram to predict the risk of lymph node metastasis was constructed. The model was confirmed using bootstrap resampling, and an independent validation cohort contained 156 patients from June 2017 to February 2020 at another institution.
Six factors [age, tumor location, histology, the lymph node maximum standardized uptake value (SUVmax), the tumor SUVmax and the carcinoembryonic antigen (CEA) value] were identified and entered into the nomogram. The nomogram developed based on the analysis showed robust discrimination, with an area under the receiver operating characteristic curve of 0.858 in the primary cohort and 0.749 in the validation cohort. The calibration curve for the probability of lymph node metastasis showed excellent concordance between the predicted and actual results. Decision curve analysis suggested that the nomogram was clinically useful.
We set up and validated a novel and effective nomogram that can predict the risk of lymph node metastasis for individual patients with T1-2 NSCLC. This model may help clinicians to make treatment recommendations for individuals.
准确预测非小细胞肺癌(NSCLC)淋巴结转移的风险水平对其治疗至关重要。本研究旨在构建一种新型列线图,以基于正电子发射断层扫描/计算机断层扫描(PET/CT)和临床特征来识别T1-2期NSCLC患者发生淋巴结转移的风险。
回顾性分析2011年1月至2017年11月期间318例因临床T1-2期NSCLC在手术切除前30天内接受PET/CT检查的连续患者的记录。构建了一个预测淋巴结转移风险的列线图。该模型通过自助重采样进行验证,另一个机构纳入了2017年6月至2020年2月期间的156例患者作为独立验证队列。
确定了六个因素[年龄、肿瘤位置、组织学类型、淋巴结最大标准化摄取值(SUVmax)、肿瘤SUVmax和癌胚抗原(CEA)值]并纳入列线图。基于分析得出的列线图显示出强大的辨别能力,在主要队列中受试者操作特征曲线下面积为0.858,在验证队列中为0.749。淋巴结转移概率的校准曲线显示预测结果与实际结果之间具有良好的一致性。决策曲线分析表明该列线图具有临床实用性。
我们建立并验证了一种新型有效的列线图,可预测T1-2期NSCLC个体患者发生淋巴结转移的风险。该模型可能有助于临床医生为个体患者制定治疗建议。